I (and many of the readers here) have long thought that stem cells are perhaps the most overhyped medical technology out there – at least for now. I definitely agree that the possibilities for their use are staggering, and I very much hope that some of these pan out, but the gap between those possibilities and the current reality is just as huge. And it’s a gap that really shows how hard medical progress is compared to how hard it is in the public imagination.
Nature has an article that bears on this, and on some other important topics. They’ve found that stem cell treatments are being sold to patients in Texas.
(The investigation) suggests that (Celltex Therapeutics) has supplied adult stem cells to Texas doctors who offer unproven treatments to patients, and that the company is involved in these treatments. One doctor claims that the treatments are part of a clinical study run by Celltex and that the company pays him US$500 a time to inject the cells into patients, who are charged up to $25,000 for a course. The US Food and Drug Administration (FDA) considers it to be a crime to inject unapproved adult stem cells into patients. David Eller, chief executive of Celltex, denies that the company is involved in treatment procedures, but would not comment on Nature’s findings about how its cells are used or answer questions about them.
This makes me wonder about what is going on down there in Texas (and I can tell you, as an Arkansan, I’m willing to believe just about anything in that department). This latest business reminds me of the Burzynski cancer treatment stuff, in the way that definitions of “clinical trial” are stretched like rubber bands. Personally, I think that clinical trials are supposed to follow something very much like Yog’s Law in publishing (“Money flows towards the writer”). If you’re being asked to put up all kinds of money to get your book edited and published, you’re very likely being scammed. And if you’re being asked to pay thousands of dollars to be in a “clinical trial”, well. . .you’re being sold something. Real clinical trials reimburse their patients for time and effort, with money and/or medical care. They do not bill them for 25 long ones at the end of the dosing schedule
I should mention here that Slate also had an article up on Celltex, but there have been some problems. They’ve taken the piece down, citing editorial problems, but (as you’d figure), the cherchez le lawsuit rule applies here. Nature, though, doesn’t seem to be getting sued for what they’ve written.
Now, back to the stem cell treatments. Among other things, Nature mentions a blog by a woman in Texas, who’s written about her experiences being treated with adult stem cells from Celltex. It appears that she’s receiving these treatments for multiple sclerosis, and was told that “This method has been successful with auto immune diseases such as Parkinson’s, arthritis, Multiple Sclerosis as well as others.” She had apparently had a similar procedure done earlier in Mexico, but then:
“. . .a friend told Larry about a doctor in Houston who went to South Korea two years ago for a stem cell transplant to treat the debilitating effects of psoriatic arthritis. He is now able to continue his medical practice, perform surgeries, and live without pain. Because our friends had noticed progress from my first stem cell transplant, they wanted us to know that Dr. Jones was now licensed to perform the procedure in Houston. To say the least, we were both excited about the possibilities and timing.”
As that extract illustrates, at no point (that I have found) does this patient mention the phrase “clinical trial”. One gets the strong impression, actually, that she believes that she is paying to undergo a new medical procedure, the latest thing, rather than participating in any kind of investigational study for a therapy that has not yet been reviewed by the FDA. The Nature writer, David Cyranoski, was able to speak with the physician involved, who says he’s treated a number of people with cells from Celltex:
Lotfi says that most of his patients claim to get better after the treatment, but he admits that there is no scientific evidence that the cells are effective. “The scientific mind is not convinced by anecdotal evidence,” he acknowledges. “You need a controlled, double-blind study. But for many treatments, that’s not possible. It would take years, and some patients don’t have years.”
“The worst-case scenario is that it won’t work,” he adds. “But it could be a panacea, from cosmetics to cancer.” He says that Celltex is conducting a trial in which patients “will be their own control”. “If you can compare before and after and show improvement, there’s no need for a placebo,” he explains. “How can you charge people, and then give them a placebo?”
Indeed! Maybe you could try not charging them, and not making them spend their own money to find out whether your treatment is any good. Maybe you could get a large, statistically significant number of people together, who’ve been given thorough diagnostic workups, and give half of them the best standard of care for multiple sclerosis and half of them the stem cell treatment – at your expense – and see if they get better. How about that? (Oh, and just a little note – the worst case is not that nothing happens at all. It might be good for the people involved to think about that a bit).
This gets back to the discussions we’ve had around here about rethinking clinical trials. One of the things I’ll say for the FDA is that they do force people to be rigorous, and to put new medical ideas to well-controlled tests. My worry about the “sell, then test” ideas was summed up in the first link in this paragraph: “I fear that there are any number of entrepreneurial types who would gladly stretch things out, as long as someone else is paying, in the hopes of finally seeing something useful. No one will – or should – pay for extending fishing expeditions.” Read that Celltex article and see if that sounds familiar.